Literature DB >> 32696244

Modern oncological and operative outcomes in oesophageal cancer: the St. James's hospital experience.

Noel E Donlon1, Narayanasamy Ravi2, Sinead King2, Moya Cunninhgam2, Sinead Cuffe2, Maeve Lowery2, Carmel Wall2, Niall Hughes2, Cian Muldoon2, Ciara Ryan2, Jenny Moore2, Catherine O'Farrell2, Claire Gorry2, Ann-Marie Duff2, Cathy Enright2, Tim S Nugent2, Jessie A Elliot2, Claire L Donohoe2, John V Reynolds2.   

Abstract

BACKGROUND: Oesophageal cancer has a reputation for poor survival, and a relatively high risk of major postoperative morbidity and mortality. Encouragingly, a recent international cancer registry study reports a doubling of survival outcomes in Ireland over the last 20 years. This study focused on both oncologic and operative outcomes in patients treated with curative intent requiring surgery at a high-volume center.
METHODS: All patients undergoing surgery or multimodal therapy with curative intent from 2009 to 2018 were studied. All data was recorded prospectively and maintained internally. The period 2009-2013 was compared with 2014-2018 to monitor any change in trends.
RESULTS: Four hundred and seventy-five patients (adenocarcinoma 77%, mean age 65; 76% male; 64% neoadjuvant therapy) underwent open surgical resection, 54% via en bloc 2-stage, 19.8% en bloc 3-stage, and 26.5% by a transhiatal approach. New onset atrial fibrillation was the commonest index complication, in 108 (22.7%), 80 (18%) developed suspected pneumonia/respiratory tract infection, 20 (4.2%) an anastomotic leak, and 25 (5.2%) a chyle leak. The 90-day mortality rate was 1.2% and 0.8% at 30 days. The median survival was 77.17 months, with a 5-year survival of 56%.
CONCLUSION: Consistent with registry data on population survival for oesophageal cancer, this study highlights markedly improved survival outcomes in patients treated curatively, reflecting international trends, as well as low mortality rates; however, cardiorespiratory complications remain significant.

Entities:  

Keywords:  Anastomotic leak; Oesophageal adenocarcinoma; Oesophageal cancer incidence; Oesophageal squamous cell carcinoma; Oesophageal surgery complications; Oncological outcomes

Mesh:

Year:  2020        PMID: 32696244     DOI: 10.1007/s11845-020-02321-4

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  1 in total

1.  Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.

Authors:  Melina Arnold; Mathieu Laversanne; Linda Morris Brown; Susan S Devesa; Freddie Bray
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

  1 in total
  4 in total

1.  Successful maintenance of process and outcomes for oesophageal cancer surgery in Ireland during the first wave of the COVID-19 pandemic.

Authors:  Jarlath C Bolger; Noel E Donlon; Waqas Butt; Colm Neary; Mohammed Al Azzawi; Orla Brett; Sinead King; Eithne Downey; Mayilone Arumugasamy; Thomas Murphy; William B Robb; Chris G Collins; Paul A Carroll; Claire L Donohoe; Narayanasamy Ravi; John V Reynolds
Journal:  Ir J Med Sci       Date:  2021-03-16       Impact factor: 2.089

2.  Exercise-based dysphagia rehabilitation for adults with oesophageal cancer: a systematic review.

Authors:  Anna Gillman; Michelle Hayes; Greg Sheaf; Margaret Walshe; John V Reynolds; Julie Regan
Journal:  BMC Cancer       Date:  2022-01-10       Impact factor: 4.430

Review 3.  Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence.

Authors:  Andreas R R Weiss; Noel E Donlon; Hans J Schlitt; Christina Hackl
Journal:  Langenbecks Arch Surg       Date:  2021-12-03       Impact factor: 2.895

4.  Prevalence, nature and trajectory of dysphagia postoesophageal cancer surgery: a prospective longitudinal study protocol.

Authors:  Michelle Hayes; Anna Gillman; Brona Wright; Sean Dorgan; Ian Brennan; Margaret Walshe; Claire Donohoe; John V Reynolds; Julie Regan
Journal:  BMJ Open       Date:  2022-09-22       Impact factor: 3.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.